Global Uterine Fibroids Treatment Market - 2019-2026
|出版日期||內容資訊||英文 218 Pages
|子宮肌瘤治療的全球市場:2019年∼2026年 Global Uterine Fibroids Treatment Market - 2019-2026|
|出版日期: 2020年09月30日||內容資訊: 英文 218 Pages||
Global Uterine Fibroids Treatment Market Expected to reach a high CAGR by 2027: DataM Intelligence
Uterine Fibroids are the most common benign, non-cancerous tumors of a woman's uterus, most often seen during the childbearing years.
Fibroids are only treated if they cause symptoms and treatment options to range from medications to invasive surgery.
The global Uterine Fibroids Treatment market has significant opportunities to grow.
The market is primarily driven by increasing patient pool owing to increasing female geriatric population, growing prevalence of hormonal disorders and changing lifestyle.
Around 700,000 women in seven major market countries have symptoms severe enough to require surgery or radical treatment.
However, high R&D cost is likely to hinder market growth.
The global Uterine Fibroids Treatment market report segments the market by type, by treatment type, and by region.
Based on the type of fibroid, the market comprises Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated.
Of these, intramural fibroids hold the most significant market share.
Based on treatment type, the market is categorized into hormone therapy, gonadotropin-releasing hormone agonists, uterine artery embolization, myomectomy, and hysterectomy. Drug therapy is an option for some women with fibroids.
Treatment options for traditional surgical procedures include abdominal myomectomy and hysterectomy. Other non-standard but new treatments available for uterine fibroids include Radiofrequency ablation and Anti-hormonal drugs.
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America dominates the market for Uterine Fibroids Treatment owing to millions of women in the US having fibroids.
National Uterine Fibroids Foundation estimates that as many as 80% of all women in the US have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment.
The report profiles the following companies in Uterine Fibroids Treatment market - Allergan, Gedeon Richter, Repros, Bayer HealthCare, AbbVie, Movant, ObsEva and so on.
Key Points Covered in the Report
By Treatment Type
Gonadotropin-releasing hormone agonists
Uterine artery embolization
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World
Visualize the composition of Uterine Fibroids Treatment market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market - level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for crucial Uterine Fibroids Treatments of all major market players
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes